Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBTX Stock Forecast 2026-2027
$37.53
Current Price
$1.91B
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to NBTX Price Targets
+84.3%
To High Target of $69.17
+3.7%
To Median Target of $38.92
-22.0%
To Low Target of $29.28
NBTX Price Momentum
-6.3%
1 Week Change
+3.5%
1 Month Change
+608.1%
1 Year Change
+62.3%
Year-to-Date Change
-34.3%
From 52W High of $57.14
+661.3%
From 52W Low of $4.93
📊 TOP ANALYST CALLS
Did NBTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nanobiotix is one of their latest high-conviction picks.
Latest NBTX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NBTX has a bullish consensus with a median price target of $38.92 (ranging from $29.28 to $69.17). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $37.53, the median forecast implies a 3.7% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBTX Analyst Ratings
5
Buy
2
Hold
0
Sell
NBTX Price Target Range
Low
$29.28
Average
$38.92
High
$69.17
Current: $37.53
Latest NBTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | Jonathan Chang | Outperform | Maintains | $46.00 |
| May 1, 2026 | UBS | Neutral | Maintains | $N/A | |
| Apr 2, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Feb 6, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 4, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Aug 28, 2024 | Guggenheim | Buy | Initiates | $N/A | |
| Dec 8, 2023 | Leerink Partners | Outperform | Initiates | $N/A | |
| Jan 6, 2021 | Evercore ISI Group | Outperform | Initiates | $N/A |
Nanobiotix S.A. American Depositary Shares (NBTX) Competitors
The following stocks are similar to Nanobiotix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nanobiotix S.A. American Depositary Shares (NBTX) Financial Data
Nanobiotix S.A. American Depositary Shares has a market capitalization of $1.91B with a P/E ratio of -74.4x. The company generates $37.30M in trailing twelve-month revenue with a -73.5% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -196.4% and return on equity of +28.4%.
Valuation Metrics
Market Cap
$1.91B
Enterprise Value
$2.26B
P/E Ratio
-74.4x
PEG Ratio
483.9x
Price/Sales
58.5x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-196.4%
Net Margin
-73.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.9%
Current Ratio
1.1x
Debt/Equity
-1.3x
ROE
+28.4%
ROA
-10.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nanobiotix S.A. American Depositary Shares (NBTX) Business Model
About Nanobiotix S.A. American Depositary Shares
What They Do
Develops innovative cancer treatment solutions.
Business Model
Nanobiotix operates by enhancing existing radiotherapy methods through its proprietary NanoXray platform, which targets cancer cells more precisely while sparing healthy tissue. The company generates revenue by offering advanced treatment options that improve patient outcomes for various solid tumors, thereby creating value in the oncology market.
Additional Information
Nanobiotix provides American Depositary Receipts (ADRs) for investors in the U.S., highlighting its global engagement in biotechnology and the increasing interest in innovative cancer therapies. The company's focus on cutting-edge research positions it as a key player in transforming oncological care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Laurent Levy Ph.D.
Country
France
IPO Year
2020
Website
www.nanobiotix.comNanobiotix S.A. American Depositary Shares (NBTX) Latest News & Analysis
Latest News
Quick Summary
Nanobiotix (NBTX) is rated a strong speculative Buy, driven by its JNJ-1900 platform. Key targets include head and neck cancer and lung cancer programs, with a $4.5B risk-adjusted opportunity.
Why It Matters
Nanobiotix's strong speculative Buy rating highlights potential high returns from its JNJ-1900 platform, particularly in lucrative cancer treatments, making it attractive for high-risk, high-reward investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Nanobiotix is transitioning to a milestone and royalty-based oncology platform, focusing on JNJ-1900 with a potential $2.6B in milestones and royalties, extending cash runway to 2029.
Why It Matters
Nanobiotix's shift to a capital-light model with JNJ-1900 reduces risk while offering substantial milestone and royalty potential, enhancing its appeal and financial stability for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Voting Rights and Shares Capital of the Company
1 month ago
Quick Summary
The news excerpt references compliance with French commercial and financial market regulations, specifically articles L.233-8 II and 223-16.
Why It Matters
The excerpt indicates regulatory compliance, which can enhance investor confidence and potentially influence stock valuations due to perceived stability and transparency in governance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reported Q1 2026 financial results and operational updates, focusing on its nanotherapeutic cancer treatment advancements.
Why It Matters
NANOBIOTIX's operational update and financial results can indicate its growth trajectory and potential market value, directly influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Nanobiotix Joins the Euronext Tech Leaders Index
1 month ago
Quick Summary
NANOBIOTIX has been included in the Euronext Tech Leaders segment and Index, enhancing its visibility to international investors as a leading biotech focused on cancer treatments.
Why It Matters
NANOBIOTIX's inclusion in the Euronext Tech Leaders segment boosts its visibility and credibility, potentially attracting more investment and enhancing its market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
NANOBIOTIX Announces Closing of Global Offering
1 month ago
Quick Summary
Nanobiotix has completed its global offering, including the full exercise of underwriters' options for additional shares. The company focuses on innovative cancer treatment solutions.
Why It Matters
The successful closing of Nanobiotix's global offering indicates strong investor interest and raises capital for cancer treatment advancements, potentially enhancing its market position and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NBTX Stock
What is Nanobiotix S.A. American Depositary Shares's (NBTX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Nanobiotix S.A. American Depositary Shares (NBTX) has a median price target of $38.92. The highest price target is $69.17 and the lowest is $29.28.
Is NBTX stock a good investment in 2027?
According to current analyst ratings, NBTX has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $37.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBTX stock?
Wall Street analysts predict NBTX stock could reach $38.92 in the next 12 months. This represents a 3.7% increase from the current price of $37.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nanobiotix S.A. American Depositary Shares's business model?
Nanobiotix operates by enhancing existing radiotherapy methods through its proprietary NanoXray platform, which targets cancer cells more precisely while sparing healthy tissue. The company generates revenue by offering advanced treatment options that improve patient outcomes for various solid tumors, thereby creating value in the oncology market.
What is the highest forecasted price for NBTX Nanobiotix S.A. American Depositary Shares?
The highest price target for NBTX is $69.17 from at , which represents a 84.3% increase from the current price of $37.53.
What is the lowest forecasted price for NBTX Nanobiotix S.A. American Depositary Shares?
The lowest price target for NBTX is $29.28 from at , which represents a -22.0% decrease from the current price of $37.53.
What is the overall NBTX consensus from analysts for Nanobiotix S.A. American Depositary Shares?
The overall analyst consensus for NBTX is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $38.92.
How accurate are NBTX stock price projections?
Stock price projections, including those for Nanobiotix S.A. American Depositary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 11:19 AM UTC